ENVVENO MEDICAL CORP (NVNO:NASDAQ)
$12.91 0 (0%)
Analysed ENVVENO MEDICAL CORP (NVNO:NASDAQ) News Sources
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
27-03-2026
yahoo.com
NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives
03-03-2026
yahoo.com
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
04-02-2026
yahoo.com
enVVeno Medical Announces Reverse Stock Split
15-01-2026
yahoo.com
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
26-11-2025
yahoo.com
Insider Buyers Lose Additional US$294k As enVVeno Medical Dips To US$6.5m
22-11-2025
yahoo.com
enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve
13-11-2025
yahoo.com
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
31-10-2025
yahoo.com
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
26-09-2025
yahoo.com
enVVeno Medical Updates Regulatory Status of VenoValve(R)
15-09-2025
yahoo.com
What is the current price of ENVVENO MEDICAL CORP (NVNO:NASDAQ)?
The current price of ENVVENO MEDICAL CORP (NVNO:NASDAQ) is $12.91.
ENVVENO MEDICAL CORP (NVNO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENVVENO MEDICAL CORP (NVNO:NASDAQ) since the previous trading day is $0.
ENVVENO MEDICAL CORP (NVNO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENVVENO MEDICAL CORP (NVNO:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for ENVVENO MEDICAL CORP (NVNO:NASDAQ)?
The most recent average sentiment score for ENVVENO MEDICAL CORP (NVNO:NASDAQ) is 50 out of 100.
What is the most recent average sentiment for ENVVENO MEDICAL CORP (NVNO:NASDAQ)?
The most recent sentiment for ENVVENO MEDICAL CORP (NVNO:NASDAQ) is .
SEC-8K** Filing Available For ENVVENO MEDICAL CORP (NVNO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.